When Cost-Effectiveness Thresholds Drift: Global HTA, MFN Pricing, And The Need For A Coherent Framework William V. Padula May 28, 2026

https://www.healthaffairs.org/content/forefront/cost-effectiveness-thresholds-drift-global-hta-mfn-pricing-and-need-coherent-framework?utm_campaign=forefront&utm_medium=email&_hsenc=p2ANqtz--Dp8BkR66_AgaO3lHHlOxAIkpdv7Y8qZf2wSdcpYCUfwsFgFNmGfD03XqKvpyH3S1ZfWuLCH6f8y7gCuWQlTM0CRkKwg&_hsmi=421319073&utm_source=hasu Greater flexibility in cost-effectiveness thresholds used by health technology assessment bodies may appear manageable in isolation. But these shifts can reshape drug pricing far beyond national boundaries.